<DOC>
	<DOCNO>NCT00348972</DOCNO>
	<brief_summary>To assess safety , tolerability , efficacy LantusÂ® ( insulin glargine ) prediabetes ( IFG IGT ) .</brief_summary>
	<brief_title>Lantus Prediabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Hyperglycemia ( either IGT , IFG , untreated type 2 diabetes ) HbA1c &lt; 7.0 % BMI &lt; 40kg/m2 Able perform moderate stationary bicycle exercise Chronic pharmacologic treatment hyperglycemia , past present CAD serum creatinine &gt; 2.0mg/dL BP &gt; 180/105 History hypoglycemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Glargine</keyword>
	<keyword>prediabetes</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>impaired fasting glucose</keyword>
</DOC>